NCT06061809 2026-02-12N-803 and PD-L1 t-haNK Combined With Bevacizumab for Recurrent or Progressive GlioblastomaImmunityBio, Inc.Phase 2 Recruiting34 enrolled
NCT06745908 2025-10-21ResQ201A: Clinical Trial Of N-803 Plus TISLELIZUMAB And DOCETAXEL Versus DOCETAXEL Monotherapy In Participants With Advanced Or Metastatic Non-Small Cell Lung CancerImmunityBio, Inc.Phase 3 Recruiting460 enrolled
NCT06710288 2025-10-20A Phase 2, Open-label, Single-arm Study Of Autologous M-CENK Adoptive Cell Therapy And N-803 (IL-15 Superagonist) In Combination With Gemcitabine In Participants With Recurrent Platinum-Resistant High-Grade Ovarian CancerImmunityBio, Inc.Phase 2 Recruiting20 enrolled